Literature DB >> 1868872

Preferential development of pre-B lymphomas with drastically down-regulated N-myc in the E mu-ret transgenic mice.

T Iwamoto1, M Pu, M Ito, M Takahashi, K Isobe, F Nagase, K Kawashima, M Ichihara, I Nakashima.   

Abstract

We established one transgenic mouse line which developed pre-B leukemic lymphomas by introducing ret cDNA driven by the SV40 promoter and the mouse immunoglobulin (Ig) enhancer. Lymphomas developed not only in the lymph nodes and the spleen but also in the thymus between the ages of 7 and 21 weeks. Analyses of cell surface phenotypes and Ig gene rearrangement revealed that these tumors were surface IgM-B220+ pre-B lymphomas. The rearrangement pattern of the Ig heavy chain locus indicated that the tumor cells were mono- or oligoclonal. Northern blot analysis showed that the ret transgene was expressed at a high level not only in the tumors but also in the prelymphomatous lymphoid tissues. We found that the expression of N-myc was dramatically down-regulated in the tumor cells, while the expression of c-myc was rather stable. Further experiments demonstrated that ret gene product did not directly down-regulate the expression of N-myc in transformed pre-B cell lines by in vitro transfection assay. From these results, we conclude that under the control of Ig enhancer, the ret transgene affected B lymphocytes at the early maturation stage as a prerequisite for transformation, preferentially generating a unique maturation stage of pre-B lymphomas whose N-myc expression was developmentally down-regulated.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1868872     DOI: 10.1002/eji.1830210805

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  5 in total

1.  Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling.

Authors:  Valerie I Brown; Junjie Fang; Keith Alcorn; Rosalind Barr; Jenny M Kim; Robert Wasserman; Stephan A Grupp
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-01       Impact factor: 11.205

Review 2.  Role of the BCR complex in B cell development, activation, and leukemic transformation.

Authors:  Susan R Rheingold; Valerie I Brown; Junjie Fang; Jenny M Kim; Stephan A Grupp
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

3.  Neuroblastoma in a transgenic mouse carrying a metallothionein/ret fusion gene.

Authors:  T Iwamoto; M Taniguchi; W Wajjwalku; I Nakashima; M Takahashi
Journal:  Br J Cancer       Date:  1993-03       Impact factor: 7.640

4.  Oncogene-linked in situ immunotherapy of pre-B lymphoma arising in E mu/ret transgenic mice.

Authors:  M Ichihara; T Iwamoto; K Isobe; M Takahashi; A Nakayama; M Pu; Y Dai; A Parashar; K Ohkus; M Kato
Journal:  Br J Cancer       Date:  1995-04       Impact factor: 7.640

5.  CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity.

Authors:  Elad Jacoby; Sang M Nguyen; Thomas J Fountaine; Kathryn Welp; Berkley Gryder; Haiying Qin; Yinmeng Yang; Christopher D Chien; Alix E Seif; Haiyan Lei; Young K Song; Javed Khan; Daniel W Lee; Crystal L Mackall; Rebecca A Gardner; Michael C Jensen; Jack F Shern; Terry J Fry
Journal:  Nat Commun       Date:  2016-07-27       Impact factor: 14.919

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.